Ying-Qi Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ying-Qi Zhao has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Jordan Gauthier
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
9 shared publications - Kevin C. Barry
Department of Pathology and ImmunoX, University of California, San Francisco, San Francisco, California
9 shared publications - Kokoro Abe
Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington
9 shared publications - Nayvin W Chew
Translational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington
9 shared publications - Renske J.E. van Den Bijgaart
Radboud University Medical Center 1 Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology Nijmegen, the Netherlands
9 shared publications - Shayan C. Avanessian
Department of Genome Sciences, University of Washington
9 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e111094
Correction: Protocol for a Sequential Multiple Assignment Randomized Trial to Improve Physical Activity and Diet Quality in Survivors of Cancer
- 21 September 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e111094
Open AccessCorrection: Protocol for a Sequential Multiple Assignment Randomized Trial to Improve Physical Activity and Diet Quality in Survivors of Cancer
- Open Access
- 13 August 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e104572
Protocol for a Sequential Multiple Assignment Randomized Trial to Improve Physical Activity and Diet Quality in Survivors of Cancer
Background: Survivors of childhood cancer have an increased risk of cardiovascular disease (CVD), but that risk may be reduced by healthy lifestyle behaviors. Objective: Using a sequential multiple assignment randomized trial (SMART) design, this study aims to test different approaches to improve physical activity (PA) and diet quality among long-term survivors of cancer at increased risk of CVD over a 12-month period. The primary study outcomes are sedentary time and Healthy Eating Index (HEI) scores. Methods: Participants were recruited from the Childhood Cancer Survivor Study cohort, with eligibility defined as current age of 18 to 54 years and at least one of three self-reported criteria: (1) 2 . Eligible participants completed baseline surveys, including a food frequency questionnaire, and had PA measured by research-grade accelerometry, and were then randomized to one of three conditions: (1) control, (2) clinician-guided action plan (sessions with the study provider every 2 months), or (3) mobile health–supported goal setting (weekly PA and monthly diet goals based on PA and diet tracker feedback). Following SMART principles, all participants’ PA levels and HEI scores were reassessed after 3 months; participants from the 2 intervention groups who did not achieve ≥20-minute per day reduction in sedentary time or a ≥4-point increase in HEI score were classified as nonresponders and rerandomized to the alternative intervention or a more intensive lifestyle coaching intervention (weekly sessions with a study health coach). Intervention participants then entered a less intensive maintenance phase from months 7 to 12. All participants’ PA levels and HEI scores were reassessed at 12 months. The target sample size was 375 participants, with 95 participants in the control group and 140 participants in each of the initial intervention groups, which will allow the study to detect changes of 0.35 SD (approximately 30 minutes per day) in sedentary time and 0.41 SD (approximately 4 points) in HEI score between the control and intervention groups (combined). Secondary analyses will test whether there are efficacy differences across intervention strategies, and which intervention sequences are associated with the greatest reduction in sedentary time and improvements in diet quality. Results: From April 2022 to August 2025, the trial completed recruitment and randomized 374 participants out of 2268 approached. The last participant in this ongoing trial is expected to complete all procedures by the end of 2026, after which the final analyses will be conducted and the results will be reported. Conclusions: Future findings will inform whether any of these intervention strategies (and/or their combinations) can improve PA levels and diet quality in survivors of cancer at increased risk of CVD.
- 13 August 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e104572
Open AccessProtocol for a Sequential Multiple Assignment Randomized Trial to Improve Physical Activity and Diet Quality in Survivors of Cancer
Background: Survivors of childhood cancer have an increased risk of cardiovascular disease (CVD), but that risk may be reduced by healthy lifestyle behaviors. Objective: Using a sequential multiple assignment randomized trial (SMART) design, this study aims to test different approaches to improve physical activity (PA) and diet quality among long-term survivors of cancer at increased risk of CVD over a 12-month period. The primary study outcomes are sedentary time and Healthy Eating Index (HEI) scores. Methods: Participants were recruited from the Childhood Cancer Survivor Study cohort, with eligibility defined as current age of 18 to 54 years and at least one of three self-reported criteria: (1) 2 . Eligible participants completed baseline surveys, including a food frequency questionnaire, and had PA measured by research-grade accelerometry, and were then randomized to one of three conditions: (1) control, (2) clinician-guided action plan (sessions with the study provider every 2 months), or (3) mobile health–supported goal setting (weekly PA and monthly diet goals based on PA and diet tracker feedback). Following SMART principles, all participants’ PA levels and HEI scores were reassessed after 3 months; participants from the 2 intervention groups who did not achieve ≥20-minute per day reduction in sedentary time or a ≥4-point increase in HEI score were classified as nonresponders and rerandomized to the alternative intervention or a more intensive lifestyle coaching intervention (weekly sessions with a study health coach). Intervention participants then entered a less intensive maintenance phase from months 7 to 12. All participants’ PA levels and HEI scores were reassessed at 12 months. The target sample size was 375 participants, with 95 participants in the control group and 140 participants in each of the initial intervention groups, which will allow the study to detect changes of 0.35 SD (approximately 30 minutes per day) in sedentary time and 0.41 SD (approximately 4 points) in HEI score between the control and intervention groups (combined). Secondary analyses will test whether there are efficacy differences across intervention strategies, and which intervention sequences are associated with the greatest reduction in sedentary time and improvements in diet quality. Results: From April 2022 to August 2025, the trial completed recruitment and randomized 374 participants out of 2268 approached. The last participant in this ongoing trial is expected to complete all procedures by the end of 2026, after which the final analyses will be conducted and the results will be reported. Conclusions: Future findings will inform whether any of these intervention strategies (and/or their combinations) can improve PA levels and diet quality in survivors of cancer at increased risk of CVD.
- Open Access
- 1 July 2026
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 82 (3)
Shift-adjusted Neyman–Pearson classifiers via single index modeling (SACSIM)
Neyman–Pearson (NP) classifiers, which aim to maximize the clinical benefit while adhering to risk constraints, are crucial in many practical fields, including early cancer detection. However, applying these classifiers can be challenging due to discrepancies between the data distributions of the source and target populations. The potential impact can be disproportionately severe for under-represented groups. We propose a semi-parametric model-based approach for adapting NP classifier decision rules to different populations while equitably controlling classification errors specific to clinical applications. Our method involves a shift-adjustment strategy that leverages a small unlabeled sample from the target population, along with minimal auxiliary information and the labeled source data. This approach enhances the applicability of the learned decision rules and ensures they are consistently tailored for the target population. We demonstrate the performance through theoretical studies and simulations and illustrate the approach with an example of a prostate cancer study.
- 1 July 2026
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 82 (3)
Open AccessShift-adjusted Neyman–Pearson classifiers via single index modeling (SACSIM)
Neyman–Pearson (NP) classifiers, which aim to maximize the clinical benefit while adhering to risk constraints, are crucial in many practical fields, including early cancer detection. However, applying these classifiers can be challenging due to discrepancies between the data distributions of the source and target populations. The potential impact can be disproportionately severe for under-represented groups. We propose a semi-parametric model-based approach for adapting NP classifier decision rules to different populations while equitably controlling classification errors specific to clinical applications. Our method involves a shift-adjustment strategy that leverages a small unlabeled sample from the target population, along with minimal auxiliary information and the labeled source data. This approach enhances the applicability of the learned decision rules and ensures they are consistently tailored for the target population. We demonstrate the performance through theoretical studies and simulations and illustrate the approach with an example of a prostate cancer study.
- 2 April 2026
- Published by Wiley in Statistics in Medicine
- Vol. 45 (8-9) , e70498
Two‐Step Error‐Controlling Classifiers With Application to Cost‐Effective Disease Diagnosis
Accurate classifiers that use novel biomarkers and readily available predictors significantly enhance decision‐making in various clinical scenarios, such as assessing the need for biopsies in cancer diagnosis. When classification performance is limited, a decision framework can be applied to rule in or rule out invasive diagnostic procedures while incorporating a neutral zone for indeterminate classifications. Building on this framework, we propose a new family of two‐step classifiers that selectively use costly biomarker testing for a targeted subset of individuals undergoing multiple evaluations. The optimal solution expands upon the Neyman‐Pearson Lemma, highlighting a vital trade‐off between the costs of expensive biomarker measurements and improving classification performance while minimizing uncertainty in the decision process. We demonstrate the practical utility of our approach through a biomarker study focused on prostate cancer diagnosis.
- 2 April 2026
- Published by Wiley in Statistics in Medicine
- Vol. 45 (8-9) , e70498
Two‐Step Error‐Controlling Classifiers With Application to Cost‐Effective Disease Diagnosis
Accurate classifiers that use novel biomarkers and readily available predictors significantly enhance decision‐making in various clinical scenarios, such as assessing the need for biopsies in cancer diagnosis. When classification performance is limited, a decision framework can be applied to rule in or rule out invasive diagnostic procedures while incorporating a neutral zone for indeterminate classifications. Building on this framework, we propose a new family of two‐step classifiers that selectively use costly biomarker testing for a targeted subset of individuals undergoing multiple evaluations. The optimal solution expands upon the Neyman‐Pearson Lemma, highlighting a vital trade‐off between the costs of expensive biomarker measurements and improving classification performance while minimizing uncertainty in the decision process. We demonstrate the practical utility of our approach through a biomarker study focused on prostate cancer diagnosis.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Gating strategy to define NK cell subsets and activation in murine tumors.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Gating strategy to define NK cell subsets and activation in murine tumors.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Interleukin-2 and interleukin-15 promote Flt3L-dependent NK cell control of cDC1 abundance.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Interleukin-2 and interleukin-15 promote Flt3L-dependent NK cell control of cDC1 abundance.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Cytokine and activating receptor stimulation leads to NK cell activation.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Cytokine and activating receptor stimulation leads to NK cell activation.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
NK cells are the predominant lymphocyte producer of Flt3l in the TME, particularly upon activation.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
NK cells are the predominant lymphocyte producer of Flt3l in the TME, particularly upon activation.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Supplementary Table S1 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Supplementary Table S1 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Data from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
NK cells play a critical role in anticancer immunity through their direct cytotoxicity and production of cytokines, such as FMS-like tyrosine kinase 3 ligand (Flt3L). NK cell production of Flt3L controls conventional type I dendritic cell (cDC1) abundance in the tumor and promotes protective immune responses. In this study, we show that NK cell production of Flt3l in the tumor is regulated by activation and that activation by IL2 and IL15 uniquely induced Flt3L expression in NK cells. In melanoma, IL2 signaling in NK cells led to increased Flt3L production, which boosted cDC1 abundance in the tumor and improved anti–PD-1 immunotherapy response. Furthermore, NK cell subsets differentially regulated Flt3l in the tumor, with CD11b−CD27+ NK cells in mouse tumors enriched for IL2 family signaling and upregulating Flt3l upon activation. Consistently, human CD56brightCD16− NK cells more strongly correlated with cDC1 and FLT3LG expression than other NK cell subsets across multiple human melanoma datasets and cancer indications. This mechanistic study of NK cell regulation of FLT3LG and control of the NK cell–cDC1 axis provides insights and strategies for the development of more effective cancer immunotherapies.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
NK cells play a critical role in anticancer immunity through their direct cytotoxicity and production of cytokines, such as FMS-like tyrosine kinase 3 ligand (Flt3L). NK cell production of Flt3L controls conventional type I dendritic cell (cDC1) abundance in the tumor and promotes protective immune responses. In this study, we show that NK cell production of Flt3l in the tumor is regulated by activation and that activation by IL2 and IL15 uniquely induced Flt3L expression in NK cells. In melanoma, IL2 signaling in NK cells led to increased Flt3L production, which boosted cDC1 abundance in the tumor and improved anti–PD-1 immunotherapy response. Furthermore, NK cell subsets differentially regulated Flt3l in the tumor, with CD11b−CD27+ NK cells in mouse tumors enriched for IL2 family signaling and upregulating Flt3l upon activation. Consistently, human CD56brightCD16− NK cells more strongly correlated with cDC1 and FLT3LG expression than other NK cell subsets across multiple human melanoma datasets and cancer indications. This mechanistic study of NK cell regulation of FLT3LG and control of the NK cell–cDC1 axis provides insights and strategies for the development of more effective cancer immunotherapies.